Adheris Health Limited · ASX:AHE
Adheris Health — Investor Presentation (April 2025)
28 slides from Adheris Health's investor presentation, Apr 1, 2025
Slide 1: Capital Raise Presentation
Capital Raise Presentation March 2025 1 Capital Raise Presentation – 2025 © 2025 MedAdvisor Solutions. All rights reserved.
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer Introduction Information in this Presentation is not intended to be relied upon as advice to investors or potential This investor presentation (Presentation) has been prepared by MedAdvisor Limited (ACN 145 327 investors and has been prepared without taking account of
Slide 3: Important Notice and Disclaimer Cont’d
Important Notice and Disclaimer Cont’d Financial Information By accepting this Presentation, you expressly disclaim that you are in a fiduciary relationship with any of All information in this Presentation is in Australian dollars ($) unless stated otherwise. A number of the Joint Lead Manager Parti
Slide 4: Important Notice and Disclaimer Cont’d
Important Notice and Disclaimer Cont’d Forward-looking statements and forecasts (cont.) To the maximum extent permitted by law, the MedAdvisor Parties: No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including
Slide 5: Important Notice and Disclaimer Cont’d
Important Notice and Disclaimer Cont’d Hong Kong United Kingdom WARNING: This Presentation has not been, and will not be, registered as a prospectus under the Neither this Presentation nor any other document relating to the offer has been delivered for approval to Companies (Winding Up and Miscellan
Slide 6: Executive Summary
Executive Summary 6 Capital Raise Presentation – 2025 © 2025 MedAdvisor Solutions. All rights reserved.
Slide 7: Executive Summary
Executive Summary • MedAdvisor Limited (MedAdvisor Solutions or Company) provides medication management solutions in Australia, New Zealand and the United States. MedAdvisor • MedAdvisor Solutions is a global leader of innovative, pharmacy-driven patient engagement solutions that provide individuali
Slide 8: Company Update
Company Update MedAdvisor Solutions is a global leader of innovative, pharmacy-driven patient engagement solutions that provide individualised patient experiences to help remove barriers to care. Delivered 1H FY25 group revenue of $57.1M and positive EBITDA of $4.8m. Profit Optimised cost base to si
Slide 9: Company Overview
Company Overview 9 Capital Raise Presentation – 2025 © 2025 MedAdvisor Solutions. All rights reserved.
Slide 10: Company Overview
Company Overview Our Focus US: Primary focus is targeted patient engagement programs for pharma, delivered through the patient’s pharmacy. Provider prescribes… • Each delivered communication generates a transaction fee. • As US programs transition to an omnichannel approach, powered by our AI enable
Slide 11: 1H FY25 Results & Initiatives
1H FY25 Results & Initiatives Results 1H FY25 revenue of $57.1M • EBITDA: Remained positive despite a challenging trading environment in the US. • Gross margin: Increase driven by a higher mix of digital down 24.4% YOY engagement and THRiV-powered programs in the US. • Revenue: Declined year-over-ye
Slide 12: Revenue Acceleration and Cost Optimisation
Revenue Acceleration and Cost Optimisation 12 Capital Raise Presentation – 2025 © 2025 MedAdvisor Solutions. All rights reserved.
Slide 13: US Business – Positioned for Growth
US Business – Positioned for Growth Addressing FY25 Challenges, Capturing Market Opportunities Sales Execution Underperforming US commercial organisation impacting growth Actions taken and underway: • Low-level sales engagement & limited customer diversification • Restructured sales team with appoin
Slide 14: US Business – Revenue and Pipeline
US Business – Revenue and Pipeline Primed for Accelerated Growth and Margin Expansion in FY26 Outlook Pipeline by Category • While trading conditions remained challenging through Q3 as the Specialty 2H FY 2025 Specialty 1H FY 2026 business transitions, there is an expectation of a stronger Q4 with 1
Slide 15: ANZ Business
ANZ Business Market Leader with Strong Track Record and Forecasted Growth Focused Strategic Initiatives Clear Pathways for Additional Growth • Continue price restructuring by standardising SaaS fees. • Increased transaction fees aligned with value to customers • Leverage recently announced Women’s H
Slide 16: Accelerated Cost-Out Program
Accelerated Cost-Out Program Delivering ~A$12.8m1 Savings between FY24 to FY26 through New Targeted Cost-Out Initiatives and Transformation 360⁰ Projected OPEX • Total expected savings in FY25 and FY26 is A$4.5m and A$8.4m, respectively. A$67.4m A$62.9m • Expected OPEX savings resulting from the imp
Slide 17: Strategic Review
Strategic Review Addressing the Valuation Disconnect Strategic Review Update • As announced to the market on 14 November 2024, the Company is currently undertaking a formal strategic review process to evaluate strategic options to maximise shareholder value. It is of the belief of the Board that Med
Slide 18: Outlook
Outlook Positioned for strong growth and higher margins Key Investment Highlights Revenue and EBITDA Guidance FY25 • Strengthened US sales structure to de-risk and accelerate revenue growth FY 23a FY 24a FY 25e • Margin expansion via Launch of THRiV next-gen Revenue A$98.0m A$122.1m A$93m – A$99m pa
Slide 19: Equity Raise
Equity Raise 19 Capital Raise Presentation – 2025 © 2025 MedAdvisor Solutions. All rights reserved.
Slide 20: Transaction overview
Transaction overview • MedAdvisor Solutions is seeking to raising A$5.0 million by way of Placement and up to A$2.0 million via SPP (Offer). • Offer Price of A$0.10 per security represents a: • 9.1% discount to the last traded price on 28 March 2025 (A$0.11) • 1.2% discount to the 5-day VWAP price (
Slide 21: Transaction overview (cont.)
Transaction overview (cont.) Transaction overview and post raise structure MDR Pre Structure Placement Shares Outstanding (m) 552.0 Placement Shares Issued (m) 50.0 Share Price (A$) 0.11 Issue Price (A$) 0.10 Market Capitalisation (A$m) 60.7 Placement Capital Raised (A$m) 5.0 MDR Post Structure SPP
Slide 22: Indicative Transaction Timetable
Indicative Transaction Timetable Key events Indicative Dates* Record Date for SPP 7.00pm (AEST) Monday, 31 March 2025 Trading Halt, Placement and SPP announced, Placement bookbuild conducted Monday, 31 March 2025 Trading halt lifted and trading resumes Tuesday, 1 April 2025 Settlement of Placement a
Slide 23: Key Risks
Key Risks 23 Capital Raise Presentation – 2025 © 2025 MedAdvisor Solutions. All rights reserved.
Slide 24: Key Risks
Key Risks Risk Description Risk Description Capital The objective of MedAdvisor’s capital management strategy is to maintain a Rising instability of Increased competition through local or global competitors could result in price strong financial position to support our current operations, prepare fo
Slide 25: Key Risks (cont.)
Key Risks (cont.) Risk Description Risk Description Insurance risk MedAdvisor may be adversely impacted if we are unable to obtain adequate Economic risk Changes in Australian, US and world economic conditions may adversely affect insurance coverage for business risks. MedAdvisor maintains insurance
Slide 26: Thank you!
Thank you! 26 Capital Raise Presentation – 2025 © 2025 MedAdvisor Solutions. All rights reserved.
Slide 27: Appendix
Appendix 27 Capital Raise Presentation – 2025 © 2025 MedAdvisor Solutions. All rights reserved.
Slide 28: Covenants & Balance Sheet
Covenants & Balance Sheet 31-Dec-24 30-Jun-24 31-Dec-23 30-Jun-23 Assets 1. Minimum Revenue Covenant Current assets Cash and cash equivalents 12,397,504 15,578,260 22,534,714 14,198,644 At the end of each month listed in the first column of the table below and in respect of the previous six- Trade a